Authors: P. Cetkovská Authors‘ workplace: Dermatovenerologická klinika FN a LFUK v Plzni přednosta prof. MUDr. Karel Pizinger, CSc. Published in: Čes-slov Derm, 85, 2010, No. 2, p. 68-75 Category: Reviews (Continuing Medical Education)
In the last years, the knowledge of pathophysiology of immune diseases and cancer increased very rapidly. Better understanding of signal transduction and metabolic pathways enables to establish potential molecular targets of therapy. Targeted therapy brings better efficacy, safety profile and possibility of long-term treatment together with improved quality of life of seriously ill patients. On the other hand, it leads to unusual and unexpected side effects in comparison to immunosupressive or anti-cancer therapy. The article introduces the side effects of new targeted agents including biologicals and some new chemotherapeutic drugs.
Key words: targeted anti-cancer therapy – biological therapy – chemotherapy – TNF α antagonists – EGFR inhibitors – multikinase inhibitors – inhibitors of proteasomes – monoclonal antibodies – skin side effects
1. AUTIER, J., ESCUDIER, B., WECHSLER, J., et al. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol, 2008, 144/7, p. 886-892.
2. BENÁKOVÁ, N., CETKOVSKÁ, P. Biologika v dermatologii. Biologická léčba, 2008, vol. 1, p. 31-37.
3. BORRÁS-BLASCO, J., NAVARRO-RUIZ, A., BORRÁS, C., CASTERÁ, E. Adverse cutaneous reactions induced by TNF-[alpha] antagonist therapy. Southern Med J, 2009, 102, p. 1133-1140.
4. CETKOVSKÁ, P., PIZINGER, K. Kožní změny při chemoterapii hematologických nemocí. Čes-slov Derm, 2001, 76(4), p. 196-200.
5. COLLAMER, AN., GUERRERO, KT., HENNING, JS., et al. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: A literature review and potential mechanisms of action. Arthritis &Rheumatism, 2008, 59, p. 996-1001.
6. HAMMOND-THELIN, LA. Cutaneous reactions related to systemic immunomodulators and targeted therapeutics. Dermatol Clin, 2008, 26, p. 121-159.
7. HEIDARY, NH., NAIK, H., BURGIN, S. Chemotherapeutic agents and the skin: An update. J Am Acad Dermatol, 2008, 58, p. 545-563.
8. LACOUTURE, ME., LAI, SE. The PRIDE (Papulopustules and/or paronychia, Regulatory abnormalities of hair growth, Itching, and Dryness due to Epidermal growth factor receptor inhibitors) syndrome. Br J Dermatol, 2006, 155 (4), p. 852-4.
9. LEE, WJ., LEE, JL., CHANG, SE., et al. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol, 2009, online early, p. 1-7.
10. LIMA, XT., SEIDLER, EM., LIMA, HC., et al. Long-term safety of biologics in dermatology. Dermatologic Therapy, 2009, 22, p. 2-21.
11. LITT, JZ. Drug eruption reference manual.14th ed. London: Informa healthcare, 2008, 658 p.
12. KRAJSOVÁ, I. Kožní projevy cílené léčby nádorů. Remedia, 2006, 16, p. 416-420.
13. MOSTOU, AE., MATEKOVITS, A., DESSINIOTI, C., et al. Cutaneous side effects of anti-tumour factor biologic therapy: a clinical course. J Am Acad Dermatol, 2009, 61, p. 486-500.
14. MYSKOWSKI, PL., HALPERN, AC. Cutaneous adverse reactions to therapeutic monoclonal antibodies for Cancer. Current Allergy and Asthma reports, 2008, 8, p.63-68.
15. OSIO, A., MATEUS, C., SORIA, J., et al. Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors. Br J Dermatol, 2009, 16/3, s. 515-521.
16. ROBERT, C., MATEUS, CH., SPATZ, A., et al. Dermatologic symptoms associated with the multikinase inhibitor sorafenib. J Am Acad Dermatol, 2009, 60, p. 299-304.
17. ROÉ, E., MURET, MPG., MARCUELLO, E., et al. Description and management of cutaneous side effects during cetuximab or erlotinib treatments: A prospective study of 30 patients. J Am Acad Dermatol, 2006, 55, p. 429-437.
18. SEGAERT, S., CHIRITESCU, G., LEMMENS, L., et al. Skin toxicities of targeted therapies. Eur J Cancer, 2009, 45, suppl.1, p. 295-308.
19. VENCOVSKÝ, J. a výbor České revmatologické společnosti. Bezpečnost biologické léčby – doporučení České revmatologické společnosti. Čes Revmatol, 2009, 17/3, s. 145-159. Web pages National Cancer Institute Fact Sheet
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
